Chelsea Therapeutics International 8-K 2006
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 1, 2006
CHELSEA THERAPEUTICS INTERNATIONAL, LTD.
(Exact name of registrant as specified in its charter)
13590 Ballantyne Corporate Place, Unit 325, Charlotte, North Carolina 28277
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code (704) 341-1516
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 1.01. Entry into a Material Definitive Agreement.
On February 1, 2006, the Board of Directors of Chelsea Therapeutics International, Ltd. (the Company) approved an amendment to the Companys 2004 Stock Plan to increase the number of shares reserved for issuance thereunder by 100,000 shares, from 1,496,432 shares to 1,596,432 shares. No other changes were made to the 2004 Stock Plan.
A copy of the 2004 Stock Plan, as amended, is attached as Exhibit 10.4 and a description of the 2004 Stock Plan can be found in our Prospectus filed pursuant to 424(b)(3) on September 1, 2005.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.